ABSTRACT
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
Footnotes
↵* Dr. Abrahamsen has disclosed financial relationships (teaching and speaking, independent contracting, or serving on advisory committees or review panels) with Amgen, Eli Lilly, Novartis, Merck, and Takeda.
- Copyright © 2015 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- No citing articles found.